An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era
Abstract Background Systemic inflammatory parameters are associated with poor outcomes in malignant patients. Several inflammation-based cumulative prognostic score systems were established for various solid tumors. However, there is few inflammation based cumulative prognostic score system for pati...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-01-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12885-017-3931-z |
| _version_ | 1819077269133459456 |
|---|---|
| author | Feifei Sun Jia Zhu Suying Lu Zijun Zhen Juan Wang Junting Huang Zonghui Ding Musheng Zeng Xiaofei Sun |
| author_facet | Feifei Sun Jia Zhu Suying Lu Zijun Zhen Juan Wang Junting Huang Zonghui Ding Musheng Zeng Xiaofei Sun |
| author_sort | Feifei Sun |
| collection | DOAJ |
| description | Abstract Background Systemic inflammatory parameters are associated with poor outcomes in malignant patients. Several inflammation-based cumulative prognostic score systems were established for various solid tumors. However, there is few inflammation based cumulative prognostic score system for patients with diffuse large B cell lymphoma (DLBCL). Methods We retrospectively reviewed 564 adult DLBCL patients who had received rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) therapy between Nov 1 2006 and Dec 30 2013 and assessed the prognostic significance of six systemic inflammatory parameters evaluated in previous studies by univariate and multivariate analysis:C-reactive protein(CRP), albumin levels, the lymphocyte-monocyte ratio (LMR), the neutrophil-lymphocyte ratio(NLR), the platelet-lymphocyte ratio(PLR)and fibrinogen levels. Results Multivariate analysis identified CRP, albumin levels and the LMR are three independent prognostic parameters for overall survival (OS). Based on these three factors, we constructed a novel inflammation-based cumulative prognostic score (ICPS) system. Four risk groups were formed: group ICPS = 0, ICPS = 1, ICPS = 2 and ICPS = 3. Advanced multivariate analysis indicated that the ICPS model is a prognostic score system independent of International Prognostic Index (IPI) for both progression-free survival (PFS) (p < 0.001) and OS (p < 0.001). The 3-year OS for patients with ICPS =0, ICPS =1, ICPS =2 and ICPS =3 were 95.6, 88.2, 76.0 and 62.2%, respectively (p < 0.001). The 3-year PFS for patients with ICPS = 0–1, ICPS = 2 and ICPS = 3 were 84.8, 71.6 and 54.5%, respectively (p < 0.001). Conclusions The prognostic value of the ICPS model indicated that the degree of systemic inflammatory status was associated with clinical outcomes of patients with DLBCL in rituximab era. The ICPS model was shown to classify risk groups more accurately than any single inflammatory prognostic parameters. These findings may be useful for identifying candidates for further inflammation-related mechanism research or novel anti-inflammation target therapies. |
| first_indexed | 2024-12-21T18:54:31Z |
| format | Article |
| id | doaj.art-ee30ea04963c48d5b9eb417925716363 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-21T18:54:31Z |
| publishDate | 2018-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-ee30ea04963c48d5b9eb4179257163632022-12-21T18:53:40ZengBMCBMC Cancer1471-24072018-01-011811810.1186/s12885-017-3931-zAn inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab eraFeifei Sun0Jia Zhu1Suying Lu2Zijun Zhen3Juan Wang4Junting Huang5Zonghui Ding6Musheng Zeng7Xiaofei Sun8State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer CenterDepartment of Biochemistry and Molecular Biology, Mayo Clinic ScottsdaleState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer CenterAbstract Background Systemic inflammatory parameters are associated with poor outcomes in malignant patients. Several inflammation-based cumulative prognostic score systems were established for various solid tumors. However, there is few inflammation based cumulative prognostic score system for patients with diffuse large B cell lymphoma (DLBCL). Methods We retrospectively reviewed 564 adult DLBCL patients who had received rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) therapy between Nov 1 2006 and Dec 30 2013 and assessed the prognostic significance of six systemic inflammatory parameters evaluated in previous studies by univariate and multivariate analysis:C-reactive protein(CRP), albumin levels, the lymphocyte-monocyte ratio (LMR), the neutrophil-lymphocyte ratio(NLR), the platelet-lymphocyte ratio(PLR)and fibrinogen levels. Results Multivariate analysis identified CRP, albumin levels and the LMR are three independent prognostic parameters for overall survival (OS). Based on these three factors, we constructed a novel inflammation-based cumulative prognostic score (ICPS) system. Four risk groups were formed: group ICPS = 0, ICPS = 1, ICPS = 2 and ICPS = 3. Advanced multivariate analysis indicated that the ICPS model is a prognostic score system independent of International Prognostic Index (IPI) for both progression-free survival (PFS) (p < 0.001) and OS (p < 0.001). The 3-year OS for patients with ICPS =0, ICPS =1, ICPS =2 and ICPS =3 were 95.6, 88.2, 76.0 and 62.2%, respectively (p < 0.001). The 3-year PFS for patients with ICPS = 0–1, ICPS = 2 and ICPS = 3 were 84.8, 71.6 and 54.5%, respectively (p < 0.001). Conclusions The prognostic value of the ICPS model indicated that the degree of systemic inflammatory status was associated with clinical outcomes of patients with DLBCL in rituximab era. The ICPS model was shown to classify risk groups more accurately than any single inflammatory prognostic parameters. These findings may be useful for identifying candidates for further inflammation-related mechanism research or novel anti-inflammation target therapies.http://link.springer.com/article/10.1186/s12885-017-3931-zDiffuse large B-cell lymphomaRituximabInflammationScore systemPrognostic |
| spellingShingle | Feifei Sun Jia Zhu Suying Lu Zijun Zhen Juan Wang Junting Huang Zonghui Ding Musheng Zeng Xiaofei Sun An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era BMC Cancer Diffuse large B-cell lymphoma Rituximab Inflammation Score system Prognostic |
| title | An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era |
| title_full | An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era |
| title_fullStr | An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era |
| title_full_unstemmed | An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era |
| title_short | An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era |
| title_sort | inflammation based cumulative prognostic score system in patients with diffuse large b cell lymphoma in rituximab era |
| topic | Diffuse large B-cell lymphoma Rituximab Inflammation Score system Prognostic |
| url | http://link.springer.com/article/10.1186/s12885-017-3931-z |
| work_keys_str_mv | AT feifeisun aninflammationbasedcumulativeprognosticscoresysteminpatientswithdiffuselargebcelllymphomainrituximabera AT jiazhu aninflammationbasedcumulativeprognosticscoresysteminpatientswithdiffuselargebcelllymphomainrituximabera AT suyinglu aninflammationbasedcumulativeprognosticscoresysteminpatientswithdiffuselargebcelllymphomainrituximabera AT zijunzhen aninflammationbasedcumulativeprognosticscoresysteminpatientswithdiffuselargebcelllymphomainrituximabera AT juanwang aninflammationbasedcumulativeprognosticscoresysteminpatientswithdiffuselargebcelllymphomainrituximabera AT juntinghuang aninflammationbasedcumulativeprognosticscoresysteminpatientswithdiffuselargebcelllymphomainrituximabera AT zonghuiding aninflammationbasedcumulativeprognosticscoresysteminpatientswithdiffuselargebcelllymphomainrituximabera AT mushengzeng aninflammationbasedcumulativeprognosticscoresysteminpatientswithdiffuselargebcelllymphomainrituximabera AT xiaofeisun aninflammationbasedcumulativeprognosticscoresysteminpatientswithdiffuselargebcelllymphomainrituximabera AT feifeisun inflammationbasedcumulativeprognosticscoresysteminpatientswithdiffuselargebcelllymphomainrituximabera AT jiazhu inflammationbasedcumulativeprognosticscoresysteminpatientswithdiffuselargebcelllymphomainrituximabera AT suyinglu inflammationbasedcumulativeprognosticscoresysteminpatientswithdiffuselargebcelllymphomainrituximabera AT zijunzhen inflammationbasedcumulativeprognosticscoresysteminpatientswithdiffuselargebcelllymphomainrituximabera AT juanwang inflammationbasedcumulativeprognosticscoresysteminpatientswithdiffuselargebcelllymphomainrituximabera AT juntinghuang inflammationbasedcumulativeprognosticscoresysteminpatientswithdiffuselargebcelllymphomainrituximabera AT zonghuiding inflammationbasedcumulativeprognosticscoresysteminpatientswithdiffuselargebcelllymphomainrituximabera AT mushengzeng inflammationbasedcumulativeprognosticscoresysteminpatientswithdiffuselargebcelllymphomainrituximabera AT xiaofeisun inflammationbasedcumulativeprognosticscoresysteminpatientswithdiffuselargebcelllymphomainrituximabera |